Skip to main content
PROTEOMICS INTERNATIONAL LABORATORIES LTD logo

PROTEOMICS INTERNATIONAL LABORATORIES LTD — Investor Relations & Filings

Ticker · PIQ ISIN · AU000000PIQ0 ASX Professional, scientific and technical activities
Open in API
Filings indexed 691 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country AU Australia
Listing ASX PIQ

About PROTEOMICS INTERNATIONAL LABORATORIES LTD

https://www.proteomics.com.au/

Proteomics International Laboratories Ltd specializes in the analysis of protein structures and functions to develop diagnostic tests and therapeutic targets. Utilizing high-resolution mass spectrometry and proprietary bioinformatics, the company identifies biomarkers for various diseases. Its primary commercial product, PromarkerD, is a predictive blood test for diabetic kidney disease that identifies at-risk patients before clinical symptoms manifest. The company also provides contract analytical services to pharmaceutical and biotechnology organizations, supporting drug discovery, biosimilar validation, and clinical trials. By integrating advanced proteomics with clinical data, the firm focuses on the commercialization of precision medicine tools and the improvement of patient management through early detection and monitoring of chronic conditions.

Recent filings

Filing Released Lang Actions
Response to ASX Price Query 4 pages 332.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX release dated 7 May 2026, consisting of a response from Proteomics International Laboratories Ltd to an ASX price query. The content includes answers to questions about recent trading activity, confirmation of compliance with ASX Listing Rules, and references to prior announcements such as quarterly activities and strategic plans. The document is a formal correspondence responding to a regulatory inquiry rather than a financial report or earnings release. It does not contain financial statements, audit information, or detailed management discussion. It is a regulatory compliance communication addressing market disclosure obligations under ASX Listing Rules, specifically Listing Rule 3.1. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance documents that do not fit other specific categories.
2026-05-06 English
Notification of Expiry of Listed Options - PIQO 4 pages 1.0MB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 1 May 2026 from Proteomics International Laboratories Ltd regarding the notification of expiry of listed options (ASX: PIQO). It includes detailed instructions for option holders on how to exercise their options before the expiry date of 31 May 2026, information about cessation of trading of the options, and a personalized Notice of Exercise form. The content is focused on informing shareholders about the expiry and exercise process of listed options, which is a capital market event related to share options. There is no financial statement, earnings data, or management discussion present. The document is not a report but an announcement about the expiry and exercise of options, which relates to capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the capital event, not just a brief notice or regulatory filing, so it is not RNS or RPA.
2026-04-30 English
Proteomics Strategic Plan 19 pages 3.2MB
Investor Presentation Classification · 92% confidence The document is a slide‐style presentation dated 28 April 2026 with forward‐looking statements, corporate overview, board profiles, strategy, product pipeline and market analysis. It reads like an investor pitch deck rather than a formal financial report, earnings release or regulatory filing. Therefore it fits the Investor Presentation category.
2026-04-27 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 565.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report - Third Quarter FY26' and includes detailed operational highlights, financial highlights, cash flow statements, and updates on board and executive changes. It contains substantive financial data such as cash flows from operating, investing, and financing activities, as well as a consolidated statement of cash flows for the quarter ending 31 March 2026. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year indicates this is a quarterly report. The document also references Appendix 4C, which is a standard quarterly cash flow report for entities listed on the ASX. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-27 English
Restructure, Executive Appointment and Board Update 2 pages 235.5KB
Board/Management Information Classification · 95% confidence The document is an ASX release announcing organisational restructuring, appointment of a new Chief Financial Officer, and retirement of a board member. It focuses on changes to senior management and the board of directors. This clearly fits the ‘Board/Management Information’ category.
2026-04-16 English
Final Director's Interest Notice 2 pages 305.0KB
Director's Dealing Classification · 99% confidence The document is titled 'Appendix 3Z Final Director's Interest Notice' and details the director’s securities holdings and relevant interests under ASX Listing Rule 3.19A.3. This is a direct report of personal share interests and transactions by a company director, matching the 'Director's Dealing' category.
2026-04-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.